Opti-DHA, from Douglas Laboratories®, is an omega-3 formula providing a novel ratio of DHA to EPA in an enteric-coated softgel for improved digestibility. This unique ratio is used to support cell membrane fluidity and allowing optimal communication between cells and hormones.
Studies have shown that DHA, along with EPA, may play an important role in cardiovascular health. One landmark study, the GISSI-Prevenzione Trial, involved over 11,000 people who had already survived myocardial infarction. This was the first large-scale trial that showed supplementation of essential fatty acids (specifically fish oil) significantly lowered the risk of death by myocardial infarction and stroke. This important trial used supplements with a higher ratio of DHA to EPA, which is different from most fish oils available in the marketplace. Opti-DHA contains 450 mg of DHA and 150 mg of EPA in each two enteric-coated soft gelatin capsules. The oil used in Opti-DHA is the highest quality available and has gone through an extensive molecular distillation process to ensure the best possible product.
Two enteric-coated softgels contain:
Marine Lipid Concentrate 1000 mg
Docosahexaenoic Acid (DHA) 450 mg
Eicosapentaenoic Acid (EPA) 150 mg
SUGGESTED USAGE: Adults take 2 softgel capsules daily with meals.